1 / 10

European Commercial Potential for Inhalation Drug Delivery in Diabetes

European Commercial Potential for Inhalation Drug Delivery in Diabetes. Interactive Analyst Briefing - 8 November 2002. Morten Soegaard, Research Analyst Pharmaceuticals Group. Agenda. Aim and purpose of the report Overview of technologies in development

sadie
Download Presentation

European Commercial Potential for Inhalation Drug Delivery in Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. European Commercial Potential for Inhalation Drug Delivery in Diabetes Interactive Analyst Briefing - 8 November 2002 Morten Soegaard, Research AnalystPharmaceuticals Group

  2. Agenda • Aim and purpose of the report • Overview of technologies in development • Drivers and restraints for inhalation insulin • Strategic challenges • Revenue forecasts • Conclusions

  3. About the research • Aim of the report • Methodology • Segmentation • Insulin • Oral diabetes medications • Inhalation insulin

  4. Technologies in Development Launch Company Technology Exubera Late 2004 Aventis/Pfizer/Inhale AERx iDMS Early 2006 Novo Nordisk/Aradigm AIR 2008 Eli Lilly/Alkermes Aerodose 2007 Aerogen Technospheres 2008 PDC

  5. Drivers and Restraints Drivers for Inhalation Insulin • Unmet need for non-invasive insulin delivery • Increased use of insulin in type 2 diabetes Restraints for Inhalation Insulin • Price of treatment • Concerns over safety • Emerging non-invasive delivery technologies • Other emerging treatments for diabetes

  6. Future Competitive Environment • Time to market • Pricing / Reimbursement • Device advantage • Relative competitiveness • Profitability

  7. Strategic Challenges • Identifying a medical need • More than a convenience technology • Expanding the patient base • Wider reimbursement • Private market

  8. Launch: mid 2005 Benelux Region: Revenue Forecasts $m

  9. Conclusions • Technologies only marginally different • Strong focus on marketing effort • Notable insulin market share, but from few patients

  10. Any Questions? For more information contact us on: Tel: +44 (0) 20 7343 8383 Email: enquiries@frost.com www.pharma.frost.com

More Related